Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report released on Sunday.
OCUL has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Ocular Therapeutix in a research note on Wednesday, October 4th. Robert W. Baird reiterated an “outperform” rating and issued a $18.00 target price on shares of Ocular Therapeutix in a research note on Thursday, September 14th.
Ocular Therapeutix Stock Up 0.2 %
NASDAQ OCUL opened at $4.14 on Friday. The company has a current ratio of 4.03, a quick ratio of 3.96 and a debt-to-equity ratio of 9.41. The stock’s 50 day moving average is $2.85 and its two-hundred day moving average is $3.75. The company has a market capitalization of $328.79 million, a price-to-earnings ratio of -3.63 and a beta of 1.07. Ocular Therapeutix has a 1-year low of $2.00 and a 1-year high of $7.96.
Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.24). Ocular Therapeutix had a negative net margin of 116.18% and a negative return on equity of 589.24%. The firm had revenue of $15.08 million during the quarter, compared to the consensus estimate of $15.41 million. Equities analysts forecast that Ocular Therapeutix will post -1.21 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of OCUL. Sectoral Asset Management Inc. acquired a new stake in Ocular Therapeutix during the 2nd quarter worth $4,142,000. Nuveen Asset Management LLC grew its holdings in Ocular Therapeutix by 376.4% during the 2nd quarter. Nuveen Asset Management LLC now owns 919,602 shares of the biopharmaceutical company’s stock worth $4,745,000 after acquiring an additional 726,569 shares during the period. Cormorant Asset Management LP acquired a new stake in Ocular Therapeutix during the 2nd quarter worth $3,328,000. Federated Hermes Inc. acquired a new stake in Ocular Therapeutix during the 1st quarter worth $3,080,000. Finally, Marshall Wace LLP acquired a new stake in Ocular Therapeutix during the 3rd quarter worth $2,207,000. Institutional investors own 54.42% of the company’s stock.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.